Emerging approaches for histone deacetylase inhibitor drug discovery

Expert Opinion on Drug Discovery

Volumn 10, Issue 6, 2015, Pages 599-613

  Zwergel, Clemens ^a,b   Valente, Sergio ^a   Jacob, Claus ^b   Mai, Antonello ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Saarland State University   (Germany)

Author keywords

Cancer; Epigenetics; Histone deacetylases; Inhibitors; Neurology; Small molecules; Viral infections

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; ISOENZYME;

ANTIVIRAL THERAPY; DISEASES; DRUG COMBINATION; DRUG DEVELOPMENT; GENE EXPRESSION; HUMAN; INFLAMMATORY DISEASE; NEOPLASM; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; ANIMAL; DRUG DESIGN; DRUG EFFECTS; DRUG POTENTIATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS; PROCEDURES;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 84929928202     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1038236     Document Type: Review

References (100)

1. Berdasco M, Esteller M. Genetic syndromes caused by mutations in epigenetic genes. Hum Genet 2013;132(4):359-83
2. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325(5942):834-40
3. Clayton AL, Hazzalin CA, MahadeVan LC. Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell 2006;23(3):289-96
4. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008;9(3):206-18
5. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009;10(1):32-42
6. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6(1):38-51
7. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26(37):5420-32
8. Zhang L, Han Y, Jiang Q, et al. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy. Med Res Rev 2015;35(1):63-84
9. Lahm A, Paolini C, Pallaoro M, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA 2007;104(44):17335-40
10. Boyault C, Sadoul K, Pabion M, Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007;26(37):5468-76
11. Outeiro TF, Marques O, Kazantsev A. Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta 2008;1782(6):363-9
12. Yao Y, Yang Y, Zhu WG. Sirtuins: nodes connecting aging, metabolism and tumorigenesis. Curr Pharm Des 2014;20(11):1614-24
13. Dinarello CA. Anti-inflammatory agents: present and future. Cell 2010;140(6):935-50
14. Gray SG. Epigenetic treatment of neurological disease. Epigenomics 2011;3(4):431-50
15. Mai A, Massa S, Rotili D, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005;25(3):261-309
16. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1(4):287-99
17. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014;124(1):30-9
18. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-84
19. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72
20. Setiadi AF, Omilusik K, David MD, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 2008;68(23):9601-7
21. West AC, Mattarollo SR, Shortt J, et al. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors. Cancer Res 2013;73(24):7265-76
22. Leder A, Leder P. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 1975;5(3):319-22
23. Bots M, Verbrugge I, Martin BP, et al. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood 2014;123(9):1341-52
24. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109(1):31-9
25. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo) 2011;64(8):525-31
26. Clinical trials. Available from: http://www.clinicaltrials.gov [Cited 20 February 2015]
27. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol 2012;6(6):637-56
28. Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with epigenetic drugs: an update. Mol Oncol 2012;6(6):657-82
29. Qiu T, Zhou L, Zhu W, et al. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol 2013;9(2):255-69
30. Garcia-Manero G, Tambaro FP, Bekele NB, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 2012;30(18):2204-10
31. Del Bufalo D, Desideri M, De Luca T, et al. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Mol Cancer 2014;13:230
32. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15(12):3970-7
33. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011;7(2):263-83
34. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25(25):3884-91
35. Valente S, Mai A. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011-2013). Expert Opin Ther Pat 2014;24(4):401-15
36. Fiskus W, Sharma S, Shah B, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 2014;28(11):2155-64
37. Munster PN, Thurn KT, Thomas S, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011;104(12):1828-35
38. Martin BP, Frew AJ, Bots M, et al. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. Int J Cancer 2011;128(11):2735-47
39. Capobianco E, Mora A, La Sala D, et al. Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PLoS One 2014;9(4):e95596
40. Tan S, Liu ZP. Natural products as zincdependent histone deacetylase inhibitors. ChemMedChem 2015;10(3):441-50
41. Guerrant W, Patil V, Canzoneri JC, Oyelere AK. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J Med Chem 2012;55(4):1465-77
42. Guerrant W, Patil V, Canzoneri JC, et al. Dual-Acting histone deacetylasetopoisomerase I inhibitors. Bioorg Med Chem Lett 2013;23(11):3283-7
43. Chen GL, Wang LH, Wang J, et al. Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay. Bioorg Med Chem Lett 2013;23(13):3891-5
44. Chen JB, Chern TR, Wei TT, et al. Design and synthesis of dual-Action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. J Med Chem 2013;56(9):3645-55
45. Tavallai S, Hamed HA, Grant S, et al. Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biol Ther 2014;15(5):578-85
46. Wang G, Niu X, Zhang W, et al. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Lett 2015;356(2 Pt B):656-68
47. Govindaraj C, Tan P, Walker P, et al. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clin Cancer Res 2014;20(3):724-35
48. Kong HS, Tian S, Kong Y, et al. Preclinical studies of YK-4-272, an inhibitor of class II histone deacetylases by disruption of nucleocytoplasmic shuttling. Pharm Res 2012;29(12):3373-83
49. Varricchio L, DellAversana C, Nebbioso A, et al. Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells. Int J Biochem Cell Biol 2014;50:112-22
50. Wells CE, Bhaskara S, Stengel KR, et al. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One 2013;8(7):e68915
51. Minami J, Suzuki R, Mazitschek R, et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 2014;28(3):680-9
52. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012;119(11):2579-89
53. McConkey DJ, White M, Yan W. HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer. Adv Cancer Res 2012;116:131-63
54. Chan CT, Qi J, Smith W, et al. Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects. Cancer Res 2014;74(24):7475-86
55. Suzuki T, Ota Y, Ri M, et al. Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. J Med Chem 2012;55(22):9562-75
56. Wagner FF, Zhang YL, Fass DM, et al. Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers. Chem Sci 2015;6(1):804-15
57. Newbold A, Matthews GM, Bots M, et al. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. Mol Cancer Ther 2013;12(12):2709-21
58. Valente S, Trisciuoglio D, De Luca T, et al. 1, 3, 4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells. J Med Chem 2014;57(14):6259-65
59. Suzuki T, Kasuya Y, Itoh Y, et al. Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly. PLoS One 2013;8(7):e68669
60. Qian C, Lai CJ, Bao R, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res 2012;18(15):4104-13
61. Wang J, Pursell NW, Samson ME, et al. Potential adVantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Mol Cancer Ther 2013;12(6):925-36
62. Needham LA, Davidson AH, Bawden LJ, et al. Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs. J Pharmacol Exp Ther 2011;339(1):132-42
63. Ossenkoppele GJ, Lowenberg B, Zachee P, et al. A phase I first-in-human study with tefinostat-A monocyte/macrophage targeted histone deacetylase inhibitor-in patients with adVanced haematological malignancies. Br J Haematol 2013;162(2):191-201
64. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102(3):673-8
65. De Bellis F, Carafa V, Conte M, et al. Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392. Cancer Res 2014;74(8):2328-39
66. Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull 2003;37(Suppl 2):5-16
67. Didonna A, Opal P. The promise and perils of HDAC inhibitors in neurodegeneration. Ann Clin Transl Neurol 2015;2(1):79-101
68. Jia H, Pallos J, Jacques V, et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntingtons disease. Neurobiol Dis 2012;46(2):351-61
69. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413(6857):739-43
70. Kim D, Frank CL, Dobbin MM, et al. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron 2008;60(5):803-17
71. Kozikowski AP, Chen Y, Gaysin A, et al. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies. J Med Chem 2007;50(13):3054-61
72. Butler KV, Kalin J, Brochier C, et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010;132(31):10842-6
73. Zhang L, Liu C, Wu J, et al. Tubastatin A/ACY-1215 improves cognition in Alzheimers disease transgenic mice. J Alzheimers Dis 2014;41(4):1193-205
74. Zhang L, Sheng S, Qin C. The role of HDAC6 in Alzheimers disease. J Alzheimers Dis 2013;33(2):283-95
75. Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 2008;3(4):e1958
76. Soragni E, Xu C, Plasterer HL, et al. Rationale for the development of 2-Aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia. J Child Neurol 2012;27(9):1164-73
77. Seo J, Howell MD, Singh NN, Singh RN. Spinal muscular atrophy: an update on therapeutic progress. Biochim Biophys Acta 2013;1832(12):2180-90
78. EVans MC, Cherry JJ, Androphy EJ. Differential regulation of the SMN2 gene by individual HDAC proteins. Biochem Biophys Res Commun 2011;414(1):25-30
79. Harahap IS, Saito T, San LP, et al. Valproic acid increases SMN2 expression and modulates SF2/ASF and hnRNPA1 expression in SMA fibroblast cell lines. Brain Dev 2012;34(3):213-22
80. Schroeder FA, Lewis MC, Fass DM, et al. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS One 2013;8(8):e71323
81. Subramanian S, Bates SE, Wright JJ, et al. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 2010;3(9):2751-67
82. Hancock WW, Akimova T, Beier UH, et al. HDAC inhibitor therapy in autoimmunity and transplantation. Ann Rheum Dis 2012;71(Suppl 2):i46-54
83. Poljak M, Lim R, Barker G, Lappas M. Class I to III histone deacetylases differentially regulate inflammationinduced matrix metalloproteinase 9 expression in primary amnion cells. Reprod Sci 2014;21(6):804-13
84. Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009;9(3):309-19
85. Royce SG, Karagiannis TC. Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions. Curr Opin Allergy Clin Immunol 2014;14(1):44-8
86. Akimova T, Beier UH, Liu Y, et al. Histone/protein deacetylases and T-cell immune responses. Blood 2012;119(11):2443-51
87. Hsieh IN, Liou JP, Lee HY, et al. Preclinical anti-Arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Cell Death Dis 2014;5:e1166
88. Cleophas MC, Crisan TO, Lemmers H, et al. Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases. Ann Rheum Dis 2015. [Epub ahead of print]
89. Tsuji G, Okiyama N, Villarroel VA, Katz SI. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation. J Allergy Clin Immunol 2014. [Epub ahead of print]
90. Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 2013;9(5):993-1001
91. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487(7408):482-5
92. Palmisano I, Della Chiara G, DAmbrosio RL, et al. Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci USA 2012;109(34):E2284-93
93. Husain M, Cheung CY. Histone deacetylase 6 inhibits influenza A virus release by downregulating the trafficking of viral components to the plasma membrane via its substrate, acetylated microtubules. J Virol 2014;88(19):11229-39
94. Faller DV, Mentzer SJ, Perrine SP. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-Associated malignancies. Curr Opin Oncol 2001;13(5):360-7
95. Ghosh SK, Perrine SP, Williams RM, Faller DV. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood 2012;119(4):1008-17
96. Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011;29(3):255-65
97. Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 2012;4(1):5
98. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;33:245-54
99. Rafehi H, Balcerczyk A, Lunke S, et al. Vascular histone deacetylation by pharmacological HDAC inhibition. Genome Res 2014;24(8):1271-84
100. Badros A, Burger AM, Philip S, et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15(16):5250-7